Integrating Targeted Treatment and Individualized Approaches to Optimize Outcomes in Metastatic Colorectal Cancer

A CME/CE Certified Simulated Live Broadcast in the VA

Colorectal cancer (CRC) remains a major health problem in the United States. This form of cancer is curable in approximately 90% of patients when identified at early stages, yet a significant proportion of these tumors are not diagnosed until they have metastasized, and there continues to be an important clinical need for improved strategies to manage advanced CRC. However, an improved understanding of tumor biology has allowed for the development of targeted therapies to treat this disease. The evolving science of molecular markers and use of targeted approaches has allowed for more personalized approaches to the management of advanced forms of these tumors.

This case-based program will utilize the current medical literature as a basis for clinical decision-making in managing this most difficult-to-treat setting for CRC. The program will focus particularly on trials that have assessed targeted approaches and molecular markers, while considering the advantages and disadvantages of particular strategies in the context of their predicted side effect profiles.

Available until April 5, 2012.
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is sponsored by SCEPTER™. This activity is co-provided by Global Education Group and SCEPTER.